- Home
- THRD vs BUI Comparison
THRD vs BUI Comparison
Compare THRD & BUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- BUI
- Stock Information
- Founded
- THRD 2019
- BUI 2011
- Country
- THRD United States
- BUI United States
- Employees
- THRD N/A
- BUI N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- BUI Trusts Except Educational Religious and Charitable
- Sector
- THRD Health Care
- BUI Finance
- Exchange
- THRD Nasdaq
- BUI Nasdaq
- Market Cap
- THRD 513.2M
- BUI 524.6M
- IPO Year
- THRD 2022
- BUI N/A
- Fundamental
- Price
- THRD $11.45
- BUI $23.36
- Analyst Decision
- THRD Strong Buy
- BUI
- Analyst Count
- THRD 3
- BUI 0
- Target Price
- THRD $20.33
- BUI N/A
- AVG Volume (30 Days)
- THRD 218.2K
- BUI 59.8K
- Earning Date
- THRD 11-07-2024
- BUI 01-01-0001
- Dividend Yield
- THRD N/A
- BUI 6.79%
- EPS Growth
- THRD N/A
- BUI N/A
- EPS
- THRD N/A
- BUI 2.75
- Revenue
- THRD N/A
- BUI N/A
- Revenue This Year
- THRD N/A
- BUI N/A
- Revenue Next Year
- THRD N/A
- BUI N/A
- P/E Ratio
- THRD N/A
- BUI $7.77
- Revenue Growth
- THRD N/A
- BUI N/A
- 52 Week Low
- THRD $7.08
- BUI $18.73
- 52 Week High
- THRD $16.94
- BUI $24.22
- Technical
- Relative Strength Index (RSI)
- THRD 40.06
- BUI 48.85
- Support Level
- THRD $10.10
- BUI $23.02
- Resistance Level
- THRD $12.49
- BUI $23.69
- Average True Range (ATR)
- THRD 1.30
- BUI 0.30
- MACD
- THRD -0.32
- BUI 0.01
- Stochastic Oscillator
- THRD 25.00
- BUI 58.23
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options.